The Methodist Hospital Research Institute Site Number : 8400194 — Houston, Texas

The Methodist Hospital Research Institute Site Number : 8400194 is a clinical research site located in Houston, Texas, United States 77030.

Crixeo Clinical Trials Trust Score: 83/100 (GOOD). This profile has not yet been claimed by the site owner.

The Methodist Hospital Research Institute Site Number : 8400194 has participated in 1 clinical trials.

Therapeutic areas: Chronic Obstructive Pulmonary Disease.

Sponsors: Sanofi.

Is this your site?

Is this your site? Claim your profile and control the information sponsors and patients see.

Other research sites in Houston

Browse all research sites in Texas · View every site in Houston

Sponsor Feasibility Report

Trust Score: 83/100. Verification status: Not yet accredited. Patient reviews: 0. Complaints: 0.

Frequently Asked Questions

What is the Trust Score for The Methodist Hospital Research Institute Site Number : 8400194?

The Methodist Hospital Research Institute Site Number : 8400194 has a Crixeo Trust Score of 83/100 (GOOD). Trust Scores reflect trial volume, sponsor diversity, patient reviews, address verification, and accreditation status.

How many clinical trials has The Methodist Hospital Research Institute Site Number : 8400194 conducted?

The Methodist Hospital Research Institute Site Number : 8400194 has 1 clinical trials on record. Their work covers Chronic Obstructive Pulmonary Disease.

Is The Methodist Hospital Research Institute Site Number : 8400194 accredited by Crixeo Clinical Trials?

The Methodist Hospital Research Institute Site Number : 8400194 has not yet obtained Crixeo Accreditation. Site owners can claim their profile and apply for accreditation to improve visibility with sponsors and patients.

Can I submit a review or complaint about The Methodist Hospital Research Institute Site Number : 8400194?

Yes. Patients and trial participants can submit reviews and file complaints directly on this profile page. All submissions are reviewed before publication.